Expert Review of Precision Medicine and Drug Development

期刊简介：*Please note that Expert Review of Precision Medicine and Drug Development converted to a full Open Access journal from Volume 8 (2023). Previous volumes will continue to provide access through a Pay to Read model. Expert Review of Precision Medicine and Drug Development [e-ISSN 2380-8993] is an international open access journal publishing rigorously peer-reviewed review articles and original papers on the development and clinical application of medicine to be used in a personalised therapy setting. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, Expert Review of Precision Medicine and Drug Development supports the necessity to identify patients responsive to treatments and treat patient populations using a tailored approach. Articles focus on the following key areas: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this; Clinical trials within personalised therapy and drug development; Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment; Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies; Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues. Please note that the journal does not publish case reports, case series or animal studies Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points. Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. Reach an international clinical and medical audience alongside other key opinion leaders in your field by publishing with Expert Review of Precision Medicine and Drug Development , part of the Expert Collection brand. For any pre-submission enquiries, please contact the Commissioning Editor.

【译文】*请注意，《精准医学和药物开发专家评论》从第 8 卷（2023 年）转换为完整的开放获取期刊。之前的几卷将继续通过付费阅读模式提供访问。 Expert Review of Precision Medicine and Drug Development [e-ISSN 2380-8993] 是一份国际开放获取期刊，发表经过严格同行评审的评论文章和原创论文，涉及个性化治疗环境中的药物开发和临床应用。在医学界认识到一刀切的方法并不总是合适的时代，精准医学和药物开发专家评审支持识别对治疗有反应的患者并使用量身定制的方法治疗患者群体的必要性。文章重点关注以下关键领域：针对特定基因型和人群的药物的开发和应用，以及有助于实现这一目标的先进诊断技术和重要生物标志物；个性化治疗和药物开发的临床试验；疾病的筛查、预测和预防，不良事件的预测，治疗监测，代谢组学和微生物组学对治疗的影响；次要人群研究、全基因组关联研究、疾病-基因关联研究、个人基因组技术；道德和成本效益问题、对医疗保健和商业基础设施的影响以及监管问题。请注意，该杂志不发表病例报告、病例系列或动物研究。每篇评论的全面报道均辅以独特的专家集格式，包括以下部分：专家意见——对文章中提供的数据的个人看法，对未来可能重要的发展的讨论，以及随着进一步的研究产生更详细的结果而可能变得令人兴奋的研究途径；文章亮点——作者最关键点的执行摘要。一旦编辑团队评估了您的论文的适用性，它将由独立的专家审稿人进行双重匿名同行评审。通过发表《精准医学和药物开发专家评论》（专家集品牌的一部分），与您所在领域的其他关键意见领袖一起接触国际临床和医学受众。对于提交前的任何疑问，请联系委托编辑。